Atai Looks To Step Away From Ketamine Study After Posting Positive Results
Atai Life Sciences (NASDAQ: ATAI) announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The small study seemed to deliver positive results, but it also looks as if Atai needs a partner before moving forward with the drug. The study enrolled 16 healthy volunteers, each into one of four sequences of administration. The Phase 1 open-label, 4-period crossover study assessed the safety, tolerability, and pharmacokinetic profile of 60mg, 90mg and 120mg of PCN-101 delivered subcutaneously as compared to 60mg of… Read more.